Abbott Laboratories $ABT Shares Newly Acquired by Robeco Schweiz AG

Robeco Schweiz AG acquired a new position in shares of Abbott Laboratories (NYSE:ABT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,702 shares of the healthcare product maker’s stock, valued at approximately $1,354,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brucke Financial Inc. acquired a new position in Abbott Laboratories during the third quarter worth $226,000. Norris Perne & French LLP MI boosted its position in Abbott Laboratories by 112.1% during the third quarter. Norris Perne & French LLP MI now owns 334,455 shares of the healthcare product maker’s stock worth $33,054,000 after purchasing an additional 176,750 shares in the last quarter. Signaturefd LLC grew its holdings in Abbott Laboratories by 11.9% in the third quarter. Signaturefd LLC now owns 45,051 shares of the healthcare product maker’s stock valued at $4,452,000 after purchasing an additional 4,776 shares during the last quarter. BG Investment Services LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $269,000. Finally, Citizens Financial Group Inc. RI grew its holdings in Abbott Laboratories by 4.4% in the third quarter. Citizens Financial Group Inc. RI now owns 135,452 shares of the healthcare product maker’s stock valued at $13,387,000 after purchasing an additional 5,750 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABT. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their price target for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research report on Thursday, August 13th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. BTIG Research dropped their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a report on Thursday. Finally, Barclays started coverage on shares of Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.32.

Abbott Laboratories Stock Up 0.0%

Shares of NYSE:ABT opened at $103.70 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The stock’s fifty day simple moving average is $105.15 and its 200-day simple moving average is $98.29.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is 94.03%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.